All In Biotech

Free tool

FAERS Monitor: Arakoda

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210607 or its brand name (Arakoda, Tafenoquine Succinate). Reports on generic versions are filed under their own applications.

Reports

66

Serious

57

86% of reports

Hospitalization

27

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • depression20
  • anxiety18
  • nausea15
  • post-traumatic stress disorder15
  • anger14
  • tinnitus12
  • headache11
  • dizziness10
  • memory impairment10
  • mental disorder10
  • off label use10
  • paranoia10
  • suicide attempt10
  • brain injury9
  • mood swings9

Reports by year received

View as table
YearReports
20061
20071
201823
20195
20202
20212
20222
202311
20248
20253
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,093 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
post-traumatic stress disorderSignal15714.9457.99,973
brain injurySignal9286.4156.02,281
paranoiaSignal10185.0104.51,651
angerSignal14132.082.91,693
mood swingsSignal990.049.0707
tinnitusSignal1283.349.9897
mental disorderSignal1073.341.4643
suicide attemptSignal1052.629.7457
depressionSignal2028.019.4500
memory impairmentSignal1023.213.1192
anxietySignal1820.213.6313
dizzinessSignal106.43.641
nauseaSignal156.03.960
headacheSignal115.63.338
off label useSignal103.62.117

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.